Evidence map›Paper›PMID 32780227›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2021

Etoricoxib treatment prevented body weight gain and ameliorated oxidative stress in the liver of high-fat diet-fed rats.

Fariha Kabir, Kamrun Nahar, Md Mizanur Rahman, Fariha Mamun, Shoumen Lasker, Ferdous Khan, Tahmina Yasmin, Khondker Ayesha Akter, Nusrat Subhan, Md Ashraful Alam

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Fariha KabirDepartment of Pharmaceutical Sciences, North South University, Dhaka, 1219, Bangladesh.
Kamrun NaharDepartment of Pharmaceutical Sciences, North South University, Dhaka, 1219, Bangladesh.
Md Mizanur RahmanDepartment of Pharmaceutical Sciences, North South University, Dhaka, 1219, Bangladesh.
Fariha MamunDepartment of Pharmaceutical Sciences, North South University, Dhaka, 1219, Bangladesh.
Shoumen LaskerDepartment of Pharmaceutical Sciences, North South University, Dhaka, 1219, Bangladesh.
Ferdous KhanDepartment of Pharmaceutical Sciences, North South University, Dhaka, 1219, Bangladesh.
Tahmina YasminDepartment of Pharmaceutical Sciences, North South University, Dhaka, 1219, Bangladesh.
Khondker Ayesha AkterDepartment of Pharmaceutical Sciences, North South University, Dhaka, 1219, Bangladesh.
Nusrat SubhanDepartment of Pharmaceutical Sciences, North South University, Dhaka, 1219, Bangladesh.
Md Ashraful AlamDepartment of Pharmaceutical Sciences, North South University, Dhaka, 1219, Bangladesh. sonaliagun@yahoo.com.ORCID 0000-0001-7596-5868
North South University · BD

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The main focus of this study was to determine the role of etoricoxib in counterbalancing the oxidative stress, metabolic disturbances, and inflammation in high-fat (HF) diet-induced obese rats. To conduct this study, 28 male Wistar rats (weighing 190-210 g) were distributed randomly into four groups: control, control + etoricoxib, HF, and HF + etoricoxib. After 8 weeks of treatment with etoricoxib (200 mg/kg), all the animals were sacrificed followed by the collection of blood and tissue samples in order to perform biochemical tests along with histological staining on hepatic tissues. According to this study, etoricoxib treatment prevented the body weight gain in HF diet-fed rats. Furthermore, rats of HF + etoricoxib group exhibited better blood glucose tolerance than the rats of HF diet-fed group. In addition, etoricoxib also markedly normalized HF diet-mediated rise of hepatic enzyme activity. Etoricoxib treatment lowered the level of oxidative stress indicators significantly with a parallel augmentation of antioxidant enzyme activities. Furthermore, etoricoxib administration helped in preventing inflammatory cell invasion, collagen accumulation, and fibrotic catastrophe in HF diet-fed rats. The findings of the present work are suggestive of the helpful role of etoricoxib in deterring the metabolic syndrome as well as other deleterious pathological changes afflicting the HF diet-fed rats.

Indexed as

AnimalsAntioxidantsCatalaseCyclooxygenase 2 InhibitorsDiet, High-FatEtoricoxibGlutathioneLiverMaleMalondialdehydeMetabolic SyndromeOxidative StressPeroxidaseRatsRats, WistarSuperoxide DismutaseAntioxidantsCatalaseCyclooxygenase 2 InhibitorsEtoricoxibGlutathioneMalondialdehydePeroxidaseSuperoxide DismutaseCOX-2EtoricoxibInflammationMetabolic syndromeObesityOxidative stress

Identifiers

PMID32780227
OpenAlexW3048550419

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.